Tags : Cinfa Biotech

Biosimilars M&A

Mundipharma Acquires Cinfa Biotech for Expansion of its Biosimilar Portfolio

Shots: Mundipharma acquires all shares of the parent company of Cinfa, Infarco including Pelmeg (pegfilgrastim, biosimilar) having global market value $4.5B The acquisition focuses on expansion of biosimilar platform by developing multiple biosimilars indicated across various therapy areas Pelmeg is a granulocyte-colony stimulating factor (GCSF) used for the treatment of CT-induced neutropenia and also received […]Read More